CN1165298C - 化合物作为抗菌剂的新用途 - Google Patents

化合物作为抗菌剂的新用途 Download PDF

Info

Publication number
CN1165298C
CN1165298C CNB008082162A CN00808216A CN1165298C CN 1165298 C CN1165298 C CN 1165298C CN B008082162 A CNB008082162 A CN B008082162A CN 00808216 A CN00808216 A CN 00808216A CN 1165298 C CN1165298 C CN 1165298C
Authority
CN
China
Prior art keywords
use according
proton pump
releasing
alkyl
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008082162A
Other languages
English (en)
Chinese (zh)
Other versions
CN1354658A (zh
Inventor
A
A·埃克
J·劳德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nicox SA
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9902027A external-priority patent/SE9902027D0/xx
Priority claimed from SE9904704A external-priority patent/SE9904704D0/xx
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1354658A publication Critical patent/CN1354658A/zh
Application granted granted Critical
Publication of CN1165298C publication Critical patent/CN1165298C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNB008082162A 1999-06-01 2000-05-25 化合物作为抗菌剂的新用途 Expired - Fee Related CN1165298C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9902027A SE9902027D0 (sv) 1999-06-01 1999-06-01 New use
SE99020273 1999-06-01
SE9904704A SE9904704D0 (sv) 1999-12-21 1999-12-21 New use
SE99047045 1999-12-21

Publications (2)

Publication Number Publication Date
CN1354658A CN1354658A (zh) 2002-06-19
CN1165298C true CN1165298C (zh) 2004-09-08

Family

ID=26663588

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008082162A Expired - Fee Related CN1165298C (zh) 1999-06-01 2000-05-25 化合物作为抗菌剂的新用途

Country Status (27)

Country Link
US (2) US6593339B1 (https=)
EP (1) EP1196155B1 (https=)
JP (1) JP4818516B2 (https=)
KR (1) KR100671392B1 (https=)
CN (1) CN1165298C (https=)
AR (1) AR024159A1 (https=)
AT (1) ATE272396T1 (https=)
AU (1) AU780678B2 (https=)
BG (1) BG106158A (https=)
BR (1) BR0011116A (https=)
CA (1) CA2373653C (https=)
CZ (1) CZ20014289A3 (https=)
DE (1) DE60012745T2 (https=)
EE (1) EE200100647A (https=)
HK (1) HK1045814B (https=)
HU (1) HUP0201502A3 (https=)
IL (1) IL146407A0 (https=)
IS (1) IS6185A (https=)
MX (1) MXPA01012295A (https=)
NO (1) NO20015855L (https=)
NZ (1) NZ515317A (https=)
PL (1) PL352744A1 (https=)
RU (1) RU2252032C2 (https=)
SK (1) SK17392001A3 (https=)
TR (1) TR200103474T2 (https=)
TW (1) TWI243672B (https=)
WO (1) WO2000072838A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1126838A4 (en) 1998-10-30 2005-02-16 Nitromed Inc NITROSIS AND NITROSYAL NON-STEROID ANTI-INFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
TWI243672B (en) * 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
CA2393724A1 (en) 1999-12-23 2001-06-28 Nitromed, Inc. Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
JP4092203B2 (ja) 2000-12-21 2008-05-28 ニトロメッド，インク． 新規のシクロオキシゲナーゼ２選択的阻害剤としての置換アリール化合物、組成物、および使用方法
EP1219306A1 (en) * 2000-12-29 2002-07-03 Nicox S.A. Compositions comprising cyclodextrins and NO- releasing drugs
EP2260837A1 (en) 2001-06-01 2010-12-15 Pozen, Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US7781396B2 (en) * 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
US20040052928A1 (en) * 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
EP1336602A1 (en) * 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
WO2003103602A2 (en) * 2002-06-11 2003-12-18 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
AU2003279622A1 (en) 2002-06-28 2004-01-19 Nitromed, Inc. Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use
CA2491127A1 (en) 2002-07-03 2004-01-15 Nitromed, Inc. Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
AU2003261281A1 (en) 2002-07-29 2004-02-16 Nicox S.A. Cyclooxygenase- 2 selective inhibitors, compositions and methods of use
WO2004012659A2 (en) 2002-08-01 2004-02-12 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
AU2003283096A1 (en) * 2002-11-05 2004-06-07 Merck Frosst Canada And Co. Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
US7491699B2 (en) * 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
ATE426575T1 (de) * 2003-01-07 2009-04-15 Univ Ramot Peptidenanostrukturen die fremdmaterial enthalten,und verfahren zur herstellung derselben
SE0301880D0 (sv) * 2003-06-25 2003-06-25 Astrazeneca Uk Ltd New drug delivery composition
JP5137400B2 (ja) * 2003-06-30 2013-02-06 テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル．ピー． アミロイド関連疾患を診断および処置するためのペプチド、それに対する抗体、ならびにその使用方法
US20050054714A1 (en) * 2003-07-17 2005-03-10 Benito Munoz Nitric oxide releasing drugs for Alzheimer's disease
JP4917889B2 (ja) 2003-09-25 2012-04-18 テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル．ピー． アミロイド関連疾患を処置するための組成物及びその使用方法
WO2005031362A2 (en) * 2003-10-02 2005-04-07 Ramot At Tel Aviv University Ltd. Novel antibacterial agents and methods of identifying and utilizing same
US8007847B2 (en) 2004-01-13 2011-08-30 Eytan Biderman Feeding formula appliance
WO2006006172A2 (en) * 2004-07-15 2006-01-19 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
WO2006013552A2 (en) 2004-08-02 2006-02-09 Ramot At Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
ATE539745T1 (de) 2004-08-19 2012-01-15 Univ Tel Aviv Future Tech Dev Zusammensetzungen zur behandlung von amyloid- assoziierten erkrankungen
US7786086B2 (en) * 2004-09-08 2010-08-31 Ramot At Tel-Aviv University Ltd. Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same
ATE485033T1 (de) * 2005-07-26 2010-11-15 Nicox Sa Pharmazeutische formulierung von nitrooxy- derivaten von nsar
US10004828B2 (en) * 2005-10-11 2018-06-26 Romat at Tel-Aviv University Ltd. Self-assembled Fmoc-ff hydrogels
US7879212B2 (en) * 2005-11-03 2011-02-01 Ramot At Tel-Aviv University Ltd. Peptide nanostructure-coated electrodes
JP2007275193A (ja) * 2006-04-04 2007-10-25 Fujifilm Corp 光プローブおよび光断層画像化装置
BRPI0918492A2 (pt) 2008-09-09 2015-12-01 Astrazeneca Ab uso de naproxen, ou sal farmaceuticamente aceitável do mesmo, e esomeprazol, ou sal farmaceuticamente aceitável do mesmo
EP2445499A4 (en) 2009-06-25 2013-02-27 Astrazeneca Ab METHOD FOR TREATING A PATIENT WITH RISK OF DEVELOPING A NSAID-ASSOCIATED SPURGE
CN103298826A (zh) 2010-11-15 2013-09-11 特拉维夫大学拉莫特有限公司 用于治疗淀粉样纤维形成相关疾病的二肽类似物
UA115139C2 (uk) 2011-12-28 2017-09-25 Поузен Інк. Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
CN104815330A (zh) * 2015-05-22 2015-08-05 杜林� 乙酸类非甾体抗炎药的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
SE8804629D0 (sv) 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
IL98680A0 (en) 1991-06-30 1992-07-15 Yeda Res & Dev Hydroxamate derivatives and pharmaceutical compositions containing them
IT1256345B (it) * 1992-08-20 1995-12-01 Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione
IT1256450B (it) 1992-11-26 1995-12-05 Soldato Piero Del Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302396D0 (sv) 1993-07-09 1993-07-09 Ab Astra A novel compound form
DE69412109T2 (de) * 1993-10-06 1999-01-21 Nicox S.A., Paris Salzetersaüreester mit entzündungshemmender und/oder schmerzlindernder wirkung und verfahren zu deren herstellung
AU7972294A (en) * 1993-10-07 1995-05-01 Entremed, Inc Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents
SI0759899T1 (en) 1994-05-10 1999-12-31 Nicox S.A. Nitro compounds and their compositions having anti-inflammatory, analgesic and anti-thrombotic acitivities
IT1282686B1 (it) 1996-02-26 1998-03-31 Nicox Sa Composti in grado di ridurre la tossicita' da farmaci
US5785689A (en) 1996-07-18 1998-07-28 Act Medical, Inc. Endoscopic catheter sheath position control
WO1998022117A1 (en) * 1996-11-22 1998-05-28 The Procter & Gamble Company Compositions for the treatment of gastrointestinal disorders containing bismuth, and nsaid and one or more antimicrobials
US6207855B1 (en) 1998-06-23 2001-03-27 Duke University Medical Center Stable no-delivering compounds
TWI243672B (en) * 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents

Also Published As

Publication number Publication date
DE60012745T2 (de) 2005-09-15
HK1045814A1 (en) 2002-12-13
NO20015855D0 (no) 2001-11-30
AR024159A1 (es) 2002-09-04
RU2252032C2 (ru) 2005-05-20
MXPA01012295A (es) 2002-07-30
US20040048917A1 (en) 2004-03-11
KR20020015334A (ko) 2002-02-27
CA2373653A1 (en) 2000-12-07
CZ20014289A3 (cs) 2002-05-15
NO20015855L (no) 2002-01-30
IS6185A (is) 2001-11-29
US6593339B1 (en) 2003-07-15
JP2003500442A (ja) 2003-01-07
AU5262300A (en) 2000-12-18
NZ515317A (en) 2004-05-28
IL146407A0 (en) 2002-07-25
CA2373653C (en) 2011-03-15
KR100671392B1 (ko) 2007-01-22
WO2000072838A1 (en) 2000-12-07
DE60012745D1 (de) 2004-09-09
CN1354658A (zh) 2002-06-19
HK1045814B (en) 2005-04-01
TWI243672B (en) 2005-11-21
AU780678B2 (en) 2005-04-07
PL352744A1 (en) 2003-09-08
EP1196155A1 (en) 2002-04-17
SK17392001A3 (sk) 2002-07-02
HUP0201502A3 (en) 2003-03-28
HUP0201502A2 (en) 2002-08-28
EE200100647A (et) 2003-02-17
JP4818516B2 (ja) 2011-11-16
EP1196155B1 (en) 2004-08-04
BG106158A (en) 2002-06-28
BR0011116A (pt) 2002-02-19
TR200103474T2 (tr) 2002-04-22
ATE272396T1 (de) 2004-08-15

Similar Documents

Publication Publication Date Title
CN1165298C (zh) 化合物作为抗菌剂的新用途
CN1248683C (zh) 二肽基肽酶iv抑制剂在制备治疗2型糖尿病的药物中的用途
CN1622805A (zh) 包含止泻药和埃坡霉素或埃坡霉素衍生物的组合
CN1178648C (zh) H+ 、k+ －atp酶抑制剂在制备用于增强抑制胃酸分泌的口服药物中的用途
CN87105828A (zh) 苏灵大或苏灵大钠和碱的速效组合物
CN1503670A (zh) 胃酸分泌抑制组合物
CN1311675A (zh) 具有lgE影响性能的化合物
CN1774253A (zh) 用环氧丙酯酮衍生物治疗顽固性肿瘤
CN1516600A (zh) 用于治疗肿瘤疾病的联合药物
CN1148188C (zh) 镇痛剂
CN1159305C (zh) 新的2-(n-氰基亚氨基)噻唑烷-4-酮衍生物
CN1882328A (zh) 使用含内过氧化物桥的化合物治疗幽门螺杆菌相关疾病的方法和组合物
CN1101189C (zh) 含有1－甲基碳青霉烯衍生物作为活性成分的抗幽门螺杆菌组合物
CN1270517A (zh) 抗菌剂
CN1842328A (zh) 可用作抗炎剂的α－氨基酰胺衍生物
CN1874772A (zh) 治疗隐匿性胃食管反流的咪唑并[1,2－a]吡啶衍生物
CN1592615A (zh) 含有二甲双胍和4－氧代丁酸的药物组合物及其在治疗糖尿病中的用途
CN1496259A (zh) 新用途
JP2003517434A5 (https=)
CN1917865A (zh) 有机化合物的组合
EP1881826B1 (en) Use of a benzoyl derivative of 3-aminocarbazole for the treatment of a disorder associated with the production of prostaglandin e2 (pge2)
CN1625396A (zh) 化合物尤其是卤代乙酰胺苯甲酸的脲衍生物或酯衍生物及其于治疗寄生疾病的用途
CN1430511A (zh) 存活效益
CN1655822A (zh) 含有acat抑制剂和胰岛素抵抗性改善剂的药用组合物
CN1599608A (zh) 含有格列酮和4－氧代丁酸的药物组合物以及它们治疗糖尿病的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: NICOX S. A.

Free format text: FORMER OWNER: ASTRAZENCA AB

Effective date: 20051118

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20051118

Address after: French Sophia Antti Boris

Patentee after: Nicox S. A.

Address before: Swedish Sodertalje

Patentee before: Astra Zeneca Aktiebolag

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040908

Termination date: 20110525